Asset
Napazimone
Pharming Group N.V. ADS each representing 10 ordinary shares
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05650229 | phase2 | recruiting | 2022-12-13 | 2027-10-01 | Pharming Technologies B.V. | Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease |
FDA applications (0)
This company has no applications containing this asset.